Gilead has now moved from a scheduled earnings setup into a genuine live-results phase. On Tuesday, August 4, 2026, the company reported second-quarter revenue of USD 7.8 billion, product sales of USD 7.6 billion, HIV sales of USD 5.7 billion, and Trodelvy sales of USD 457 million. At the same time, acquisition-related in-process research and development charges pushed quarterly diluted loss per share to USD 8.45 and non-GAAP diluted loss per share to USD 6.75.
That combination matters for options traders because the quarter did not resolve into a simple large-cap biotech beat or miss. Gilead also raised its 2026 product-sales outlook to USD 30.1 billion to USD 30.4 billion and lifted product-sales guidance excluding Veklury to USD 29.8 billion to USD 30.1 billion, but it still expects a full-year diluted loss because the Arcellx, Tubulis, and Ouro Medicines transactions are distorting the earnings line. The post-results question is not just whether revenue was good. It is whether the options market now treats Gilead more like a durable operating-growth story or keeps focusing on charge-heavy earnings quality.
That is a distinct phase change from the site’s earlier Gilead setup article, which focused on what GILD options might be pricing before the release. The market now has actual second-quarter sales, updated company guidance, and a clearer view of how much acquisition accounting is overwhelming the headline EPS read.
This article is for market commentary and options education only. This is not financial advice. Options trading involves risk and is not suitable for all investors. Review the site’s risk disclosure, the guide to how earnings affect options prices and implied volatility, the explainer on implied volatility (IV) in options trading: what it is and why it matters, and the primer on risk management in options trading: position sizing and probability.
What Gilead actually reported
The most important confirmed facts from Gilead’s August 4, 2026 results release were:
- Total second-quarter 2026 revenues increased 10% year over year to USD 7.8 billion.
- Total second-quarter product sales increased 8% to USD 7.6 billion.
- Product sales excluding Veklury increased 10% to USD 7.6 billion.
- HIV product sales increased 12% to USD 5.7 billion.
- Biktarvy sales increased 7% to USD 3.8 billion.
- Descovy sales increased 48% to USD 967 million.
- Trodelvy sales increased 26% to USD 457 million.
- Liver Disease portfolio sales increased 10% to USD 877 million.
- Veklury sales fell 81% to USD 23 million.
- Cell Therapy product sales fell 14% to USD 417 million, including USD 346 million for Yescarta and USD 70 million for Tecartus.
- Diluted loss per share was USD 8.45, and non-GAAP diluted loss per share was USD 6.75, mainly reflecting USD 9.08 per share of acquired IPR&D and tax expenses tied to recent acquisitions.
- Gilead generated USD 3.6 billion of operating cash flow during the quarter.
- As of June 30, 2026, cash, cash equivalents, and marketable debt securities were USD 3.2 billion, down from USD 10.6 billion at December 31, 2025, largely because of acquisitions, debt repayments, dividends, and buybacks.
- For full-year 2026, Gilead raised product-sales guidance to USD 30.1 billion to USD 30.4 billion, raised product-sales guidance excluding Veklury to USD 29.8 billion to USD 30.1 billion, cut expected Veklury sales to roughly USD 300 million, and now expects non-GAAP diluted loss per share of USD 0.65 to USD 0.30.
Those details matter because they show a quarter where the operating base improved again while the accounting presentation became even more distorted by deal activity. That creates a more complicated options read than a one-line biotech earnings headline.
Why this is a distinct event phase
Before the release, traders were still debating whether HIV growth, Trodelvy momentum, and acquisition-related guidance noise would leave the setup balanced. After the release, the debate changed:
- the sales base is now confirmed at USD 7.8 billion,
- HIV grew to USD 5.7 billion rather than merely staying solid,
- Trodelvy kept expanding while Cell Therapy stayed weak,
- Veklury became even less relevant to the core operating story,
- and the company raised its product-sales outlook even while acquisition charges crushed the earnings line.
That is enough to justify a related but distinct live-results article instead of treating August 4 as only a continuation of the August 3 setup.
Why It Matters For Options Traders
1. Gilead is now an operating-momentum versus charge-distortion story
The pre-event version of this story was about what might happen. The post-event version is about how much of the revenue strength the market is willing to honor when the earnings headline looks so weak. The sales lines were clearly constructive. The EPS lines were clearly messy.
That matters for options because a stock can report better top-line and product-level facts yet still produce a hard-to-read immediate reaction if investors do not trust the quality of the earnings presentation. The chain now has to reprice around two competing truths instead of one.
2. HIV remains the anchor, but the supporting pieces changed the tone
GILD is still defined first by HIV, and the USD 5.7 billion number matters. Biktarvy at USD 3.8 billion and Descovy at USD 967 million reinforce that the core franchise is still doing the heavy lifting. But the quarter did not stop there. Trodelvy rose to USD 457 million, Liver Disease reached USD 877 million, and the company also highlighted multiple regulatory and clinical updates.
That matters because options traders should not reduce the quarter to a single HIV read. The more diversified the growth base looks, the easier it is for the market to argue that Gilead deserves a cleaner post-event volatility reset once the acquisition noise starts to fade.
3. The guidance mix improved, but not in a clean way
Gilead raised its full-year product-sales ranges, which is the clearest constructive operating signal in the release. But it also cut expected Veklury sales and still expects a full-year diluted loss because the IPR&D and tax effects from the acquisition wave remain large.
For options traders, that creates a better educational takeaway than a simple beat or miss label. The market may decide that stronger base-business sales matter more than the charge-heavy optics. It may also decide that the accounting complexity deserves a lower-confidence multiple for now. That tension is the event.
4. Cash flow stayed strong while the balance-sheet cushion shrank
The quarter also gave the market a second layer to think about. Operating cash flow reached USD 3.6 billion in the quarter, which helps the bull case that the underlying business is still generating real cash. But cash, cash equivalents, and marketable debt securities fell to USD 3.2 billion because the company has been deploying capital aggressively.
That matters because options traders often overfocus on EPS during healthcare earnings. In this case, the operating cash flow and the reduced cash cushion can both affect how the market frames risk after the print.
Common misunderstandings and caveats
The EPS loss means the quarter itself was weak
No. The release shows that acquired IPR&D and tax expenses associated with recent acquisitions were the main reason the diluted loss per share looked so severe. The sales lines and the higher product-sales outlook point to a stronger operating quarter than the headline EPS number implies.
HIV strength means the whole event was automatically clean
Too simple. HIV remains strong, but the market still has to weigh weaker Cell Therapy performance, much lower Veklury revenue, and the fact that acquisition accounting is dominating the earnings presentation.
Higher product-sales guidance guarantees a bullish reaction
No. Stronger sales guidance can matter a lot, but it does not force a clean stock response if investors keep discounting the name for complexity, integration risk, or a lack of near-term earnings clarity.
Options pricing gives a clean directional forecast after the print
No. Options prices reflect hedging demand, uncertainty, and positioning around the event. They do not tell traders where Gilead shares must go next.
Bottom line
Gilead turned Tuesday, August 4, 2026 into a real live-results phase for options traders. Revenue reached USD 7.8 billion, product sales reached USD 7.6 billion, HIV sales reached USD 5.7 billion, Trodelvy reached USD 457 million, and the company raised both product-sales guidance ranges. At the same time, acquisition-related charges drove diluted loss per share to USD 8.45 and non-GAAP diluted loss per share to USD 6.75.
For options traders, the useful takeaway is not whether the quarter was simply strong or weak. The useful takeaway is that Gilead gave the market a better operating story than the EPS headline suggests, while still leaving enough accounting distortion and capital-allocation noise to keep the post-earnings interpretation complicated. The next job is to compare the realized move and volatility reset with how much of that conflict the options market had already priced.
This is not financial advice. Options trading involves risk and is not suitable for all investors.
Sources
- Gilead Investor Relations, “Gilead Sciences Announces Second Quarter 2026 Financial Results” (plain-text URL):
https://investors.gilead.com/news/news-details/2026/Gilead-Sciences-Announces-Second-Quarter-2026-Financial-Results/default.aspx - Gilead Investor Relations, Quarterly Results hub (plain-text URL):
https://investors.gilead.com/financials/quarterly-results/default.aspx - Gilead Investor Relations, Events and Presentations hub (plain-text URL):
https://investors.gilead.com/events-and-presentations/default.aspx - Gilead Investor Relations, “Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026” (plain-text URL):
https://investors.gilead.com/news/news-details/2026/Gilead-Sciences-to-Release-Second-Quarter-2026-Financial-Results-on-Tuesday-August-4-2026/default.aspx
